Posted On: 07/16/2016 12:48:34 PM
Post# of 72446
Saturday article on LHub.
Insider Financial Publishes New Research On Three Promising Biotechs
Date : 07/16/2016 @ 8:00AM
Source : InvestorsHub NewsWire
Stock : Cellceutix Corp. (QB) (CTIX)
Quote : 1.22 0.0 (0.00%) @ 4:00PM
Cellceutix Corp (OTCMKTS:CTIX) Is Setting Up For NewGen Antibiotic Gains
Massachusetts based Cellceutix Corp (OTCMKTS:CTIX) had a pretty tough second quarter, falling from April highs of $1.84 to current levels at circa $1.20. Across the period, however, no real company updates hit press, and it looks as though wider market sentiment played the major role in the decline. There’s a good chance, therefore, that as sentiment shifts, Cellceutix could pick up some upside momentum. Add to this chance that the company is about to kick off a pivotal trial in its lead candidate, a new generation antibiotic called Brilacidin, and it seems well worth a look.
Back in 2013, Cellceutix picked up the rights to Brilacidin in an asset sale on the back of a company called PolyMedix going bankrupt. At that point, it had just completed a phase 2a, and was heading into a pre-pivotal 2b. Cellceutix got its hands on Brilacidin for $5 million, which now looks like a bargain acquisition. Why? Because Merck picked up the rights to what is essentially the only comparable drug on the market – Cubicin – a couple of years later in an acquisition valued at $9.5 billion.
Cellceutix has spent the last two years proving that Brilacidin is comparable to Cubicin, which it has done successfully by way of a phase 2b, and to boot, it’s shown equivalence with a single dose, while Merck’s candidate requires a 7-day treatment period.
Read the Full Report on Cellceutix Corp (OTCMKTS:CTIX) at InsiderFinancial.com
Insider Financial Publishes New Research On Three Promising Biotechs
Date : 07/16/2016 @ 8:00AM
Source : InvestorsHub NewsWire
Stock : Cellceutix Corp. (QB) (CTIX)
Quote : 1.22 0.0 (0.00%) @ 4:00PM
Cellceutix Corp (OTCMKTS:CTIX) Is Setting Up For NewGen Antibiotic Gains
Massachusetts based Cellceutix Corp (OTCMKTS:CTIX) had a pretty tough second quarter, falling from April highs of $1.84 to current levels at circa $1.20. Across the period, however, no real company updates hit press, and it looks as though wider market sentiment played the major role in the decline. There’s a good chance, therefore, that as sentiment shifts, Cellceutix could pick up some upside momentum. Add to this chance that the company is about to kick off a pivotal trial in its lead candidate, a new generation antibiotic called Brilacidin, and it seems well worth a look.
Back in 2013, Cellceutix picked up the rights to Brilacidin in an asset sale on the back of a company called PolyMedix going bankrupt. At that point, it had just completed a phase 2a, and was heading into a pre-pivotal 2b. Cellceutix got its hands on Brilacidin for $5 million, which now looks like a bargain acquisition. Why? Because Merck picked up the rights to what is essentially the only comparable drug on the market – Cubicin – a couple of years later in an acquisition valued at $9.5 billion.
Cellceutix has spent the last two years proving that Brilacidin is comparable to Cubicin, which it has done successfully by way of a phase 2b, and to boot, it’s shown equivalence with a single dose, while Merck’s candidate requires a 7-day treatment period.
Read the Full Report on Cellceutix Corp (OTCMKTS:CTIX) at InsiderFinancial.com
(3)
(0)
